How was the inactivated polio vaccine tested before approval? This page documents the clinical trial history and safety data behind every IPV vaccine licensed in the US — from the 1954 Salk trial onward.
Clinical trial data for IPOL (Sanofi), the only injectable polio vaccine on the US childhood schedule. IPOL was licensed in 1990 with no control group and a 3-day safety monitoring window. The FDA-approved package insert acknowledges that deaths occurred in temporal association with vaccination — but the trial design made causal investigation impossible. IPOL is biologically distinct from Salk's 1950s polio vaccine; the historic Salk trial cannot serve as IPOL's safety basis.
> "Although no causal relationship has been established, deaths have occurred in temporal association after vaccination of infants."
No causal relationship could be established in a trial with no control group and only three days of observation — the trial design made safety assessment structurally impossible. Without a control group, there is no baseline against which to measure whether deaths occurred at a higher rate in vaccinated vs. unvaccinated infants. The 3-day monitoring window would not capture deaths occurring after the third day, regardless of cause.
Biological Composition: Vero Cells
IPOL is grown on vero cells — "a continuous line of monkey kidney cells cultivated on microcarriers." Vero cells are a continuous (immortalized) cell line, meaning they have been rendered biologically immortal through a process analogous to cancer cell transformation. These cells are used as the substrate for viral growth, and material from these cells ends up in every vial of IPOL.
Why the Salk Trial Doesn't Apply to IPOL
IPOL is a fundamentally different product from the Salk inactivated polio vaccine tested in the 1954 field trial:
The original Salk vaccine used a different cell substrate
It used a different manufacturing process
It was withdrawn from the US market in the 1960s and replaced by OPV (Sabin)
When IPOL was licensed in 1990, the historical Salk trial data was therefore not relevant — IPOL is a distinct pharmaceutical product that required its own safety evaluation
IPOL received a 3-day, no-control trial instead of placebo-controlled validation of the new product.
Summary Table
Brand
Licensed
Control
Solicited
Unsolicited
IPOL (Sanofi)
1990
None
3 days
3 days
Schedule
Dose
Timing
Dose 1
2 months
Dose 2
4 months
Dose 3
6–18 months
Dose 4 (booster)
4–6 years
Disease Context
Poliovirus causes paralytic disease in a small percentage of infected individuals (most infections are asymptomatic). Paralytic polio peaked in US epidemics in the early 1950s. Wild poliovirus has been eliminated from the Western hemisphere; the only remaining cases globally are in a few countries, and recent US cases have been traced to vaccine-derived strains from OPV used elsewhere. The CDC explicitly acknowledges that injected IPV does not prevent intestinal infection or fecal-oral transmission of poliovirus.
Was the polio vaccine (IPOL) tested with a placebo?
No. IPOL (Sanofi), the only injectable polio vaccine on the current US schedule, was licensed in 1990 with no control group at all. The safety monitoring window was only 3 days after injection. Without a control group, there is no baseline to determine whether adverse events — including deaths acknowledged in the package insert — occurred at elevated rates compared to unvaccinated infants.
Did the IPOL package insert acknowledge deaths after vaccination?
Yes. The FDA-approved IPOL package insert states that "deaths have occurred in temporal association after vaccination of infants." However, because the trial had no control group and only 3 days of monitoring, the insert adds that "no causal relationship has been established." The trial design made causal investigation structurally impossible — you cannot establish a causal relationship without a comparison group.
Is IPOL the same vaccine as the original Salk polio vaccine?
No. IPOL is a biologically distinct product from the Salk inactivated polio vaccine tested in the 1954 field trial. IPOL uses a different cell substrate (vero cells — an immortalized monkey kidney cell line), a different manufacturing process, and was licensed decades after the original Salk vaccine was withdrawn from the US market. The 1954 Salk trial data cannot serve as IPOL's safety basis because it is a different pharmaceutical product.
What are vero cells and why do they matter for the polio vaccine?
Vero cells are a continuous (immortalized) line of monkey kidney cells used as the substrate for growing poliovirus in IPOL production. "Continuous" means these cells have been rendered biologically immortal through a process analogous to cancer cell transformation. Material from these cells ends up in every vial of IPOL. This is disclosed in the FDA-approved package insert.
Can the polio vaccine prevent transmission of poliovirus?
No. The CDC explicitly acknowledges that injected IPV does not prevent intestinal infection or fecal-oral transmission of poliovirus. IPV protects the vaccinated individual from paralytic disease but does not stop them from carrying and spreading the virus. Wild poliovirus has been eliminated from the Western hemisphere, and recent US polio cases have been traced to vaccine-derived strains from oral polio vaccine (OPV) used in other countries.
This is the plain-HTML rendering of vaccines/pre-licensure/IPV Vaccines.md, served for search
engines, AI crawlers, and accessibility tools. The interactive 3D version
of this wiki lives at vaccine-safety.org.